**SUPPLEMENTAL TABLE 1.** Adverse Events (frequency) during maintenance trial testing lisdexamfetamine and placebo treatments.

|  |  |  |
| --- | --- | --- |
|  | **Lisdexamfetamine***n*=32n (%) | **Placebo***n*=29n (%) |
| All-Cause Mortality |  0 (0.0%) |  0 (0.0%) |
| Serious Adverse Events 0 (0.0%) 0 (0.0%)Adverse Events Leading to Discontinuation\* 2 (6.3%) 1 (3.4%)Adverse Events (not including Serious)\*\* |
| Decreased Appetite   |  10 (31.3%) |  4 (13.8%) |
| Dry Mouth |  6 (18.8%) |  1 (3.4%) |
| Insomnia |  6 (18.8%) |  4 (13.8%) |
| Increased Energy |  5 (15.6%) |  3 (10.3%) |
| Constipation   |  3 (9.4%) |  1 (3.4%) |
| Jittery  |  2 (6.3%) |  0 (0.0%) |
| Increased Heart Rate   |  2 (6.3%) |  1 (3.4%) |

Note: Adverse (side effect) events assessed systematically at month one of maintenance randomized double-blind placebo-controlled trial testing lisdexamfetamine versus placebo. These adverse event data are included in clinicaltrials.gov record (NCT03926052).

\* Adverse events leading to discontinuation (medical withdrawal) were reported for 2 cases in lisdexamfetamine (headache, dry eyes) and for 1 case in placebo (increased blood pressure).

\*\* Adverse events reported by >5% of participants in lisdexamfetamine or placebo treatment condition.